- Home
- TCMD vs SKYE Comparison
TCMD vs SKYE Comparison
Compare TCMD & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | SKYE |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 44.9M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCMD | SKYE |
|---|---|---|
| Price | $28.86 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $23.25 | $14.75 |
| AVG Volume (30 Days) | ★ 419.2K | 299.5K |
| Earning Date | 11-03-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $37.72 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $0.93 |
| 52 Week High | $30.24 | $5.75 |
Technical Indicators
Market Signals| Indicator | TCMD | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 68.74 | 31.56 |
| Support Level | $28.00 | $1.04 |
| Resistance Level | $30.24 | $1.27 |
| Average True Range (ATR) | 1.03 | 0.10 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 75.79 | 1.48 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.